StonvexLoading…
StonvexStonvexStonvexCore line items from DXC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $12.64B | $9.51B | $6.32B | $3.16B |
Operating Income | $970.00M | $733.00M | $470.00M | $216.00M |
Net Income | $18.00M | $159.00M | $52.00M | $16.00M |
EPS (Diluted) | $0.10 | $0.88 | $0.29 | $0.09 |
Total Assets | $12.89B | $13.18B | $13.58B | $13.44B |
Total Liabilities | $9.68B | $9.76B | $10.25B | $10.01B |
Cash & Equivalents | $1.74B | $1.73B | $1.89B | $1.79B |
Free Cash Flow OCF − CapEx | $1.04B | $867.00M | $508.00M | $143.00M |
Shares Outstanding | 178.65M | 180.16M | 181.76M | 184.96M |